# A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participants With Uncontrolled Hypertension.

> **NCT07686120** · PHASE3 · NOT_YET_RECRUITING · sponsor: **AstraZeneca** · enrollment: 286 (estimated)

## Conditions studied

- Uncontrolled Hypertension

## Interventions

- **DRUG:** baxdrostat 2mg
- **DRUG:** Placebo 2mg

## Key facts

- **NCT ID:** NCT07686120
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-30
- **Primary completion:** 2028-02-09
- **Final completion:** 2028-02-09
- **Target enrollment:** 286 (ESTIMATED)
- **Last updated:** 2026-07-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07686120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07686120, "A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participants With Uncontrolled Hypertension.". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07686120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*